GO:0015692 lead ion transport: Transport Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0015692 (lead ion transport) describes the directed movement of lead (Pb) ions into, out of, or within a cell, or between cells, by means of a transporter or pore.
• Lead is a non-essential toxic metal that can be mistransported by divalent metal transporters such as DMT1 (SLC11A2), which normally handles Fe2+, Mn2+, and other metals.
• SLC11 family proteins (DMT1/NRAMP1 and NRAMP1) provide a structural and mechanistic framework for understanding how lead ions may be translocated across membranes.
• Other metal transporters, including SLC30A10 for manganese and ferroportin for iron, illustrate the broader family of metal-ion transport proteins that can inform lead transport studies.
• Disruption of metal-ion transport is linked to human disease, including cystic fibrosis (ion transport defects) and inflammatory conditions where ion homeostasis is perturbed.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models are essential to test whether candidate transporters causally mediate lead ion transport.
Description
Lead (Pb) is a widespread environmental toxicant, and its movement across biological membranes is a critical determinant of its cellular accumulation and toxicity. GO:0015692, lead ion transport, is the Gene Ontology biological process that formally describes the directed movement of lead ions into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. Understanding this process is essential because lead has no known physiological function, yet it can exploit endogenous metal transport systems to enter cells. The structural and mechanistic characterization of metal transporters, such as the human SLC11 proteins DMT1 and NRAMP1, has begun to reveal how divalent metal ions are recognized and translocated, providing a template for understanding lead ion transport. Related transporters, including SLC30A10 for manganese and ferroportin for iron, further illustrate the diversity of metal-ion transport mechanisms that may overlap with lead handling. Because lead ion transport is not mediated by a single dedicated protein, researchers must combine genetic, biochemical, and structural approaches to identify the transporters and pathways involved. This article summarizes the current understanding of lead ion transport, the genes and proteins implicated, disease relevance, and the experimental methods, including CRISPR-based models, used to study this process.
lead ion transport At A Glance
| GO ID | GO:0015692 |
|---|---|
| GO term | lead ion transport |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Definition | The directed movement of lead (Pb) ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| Major function | Translocation of lead ions across cellular membranes or between cellular compartments |
| Related metal transporters | DMT1 (SLC11A2), NRAMP1 (SLC11A1), SLC30A10, ferroportin (SLC40A1) |
| Disease relevance | Lead toxicity, metal homeostasis disorders, ion transport-related diseases |
| Research methods | CRISPR knockout/knock-in, transport assays, structural biology, imaging |
What Is GO:0015692?
GO:0015692 (lead ion transport) is defined by the Gene Ontology as the directed movement of lead (Pb) ions into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore. In practical terms, this term captures any biological process that moves lead ions across a membrane or within a cellular compartment, whether through a dedicated lead transporter or through a transporter that normally handles other divalent metals but can also carry lead. The term is a biological_process and does not imply a specific mechanism, direction, or protein; instead, it groups together all transport events involving lead ions.
Why Is lead ion transport Important in Cell Biology?
Lead ion transport is important because lead is a toxic non-essential metal with no known beneficial role in human biology, and its entry into cells is a prerequisite for its adverse effects. The transporters that mediate lead uptake or efflux are often the same proteins that handle essential metals such as iron, manganese, and zinc, so understanding lead ion transport also illuminates normal metal homeostasis. Because lead can disrupt cellular processes after entering cells, identifying the transport pathways is a first step toward developing interventions that limit lead accumulation. Moreover, mutations in metal transporters are linked to human diseases, including cystic fibrosis and inflammatory conditions, highlighting the broader clinical relevance of ion transport mechanisms.
• Lead is a toxic metal with no physiological function, so its transport directly influences cellular toxicity.
• Divalent metal transporters such as DMT1 (SLC11A2) can mistransport lead, linking lead transport to iron and manganese homeostasis.
• Structural studies of SLC11 proteins provide a mechanistic basis for understanding how lead ions may be recognized and translocated.
• SLC30A10-mediated manganese transport demonstrates how specialized metal transporters handle toxic metals, offering a model for lead transport studies.
• Ferroportin (SLC40A1) illustrates the structural basis of ion transport and inhibition, informing how lead transport might be modulated.
• Ion transport defects are central to diseases such as cystic fibrosis, where mutations in CFTR disrupt ion movement.
• Epithelial barrier dysfunction in ulcerative colitis involves altered ion transport, showing the disease relevance of transport processes.
• Zinc transporters are essential for myeloid cell function and host defense, highlighting the immunological importance of metal transport.
• CRISPR-based models enable causal testing of candidate genes in lead ion transport.
• Understanding lead ion transport can guide chelation or transport-inhibition strategies for lead toxicity.
What Happens During lead ion transport?
Recognition and binding of lead ions at the transporter
In simple terms: First, a transporter protein must recognize and bind the lead ion.
The initial step in lead ion transport is the recognition and binding of the lead ion by a transport protein. Structural studies of the human SLC11 proteins DMT1 and NRAMP1 have revealed the architecture of the metal-binding site and the conformational changes required for metal ion transport. These proteins normally transport divalent metal ions such as Fe2+ and Mn2+, but their binding pockets can accommodate other divalent metals, providing a plausible route for lead ion recognition. The specificity of this step depends on the coordination geometry and the amino acid residues lining the binding site, which are conserved in the SLC11 family.
Conformational changes and translocation across the membrane
In simple terms: After binding, the transporter changes shape to move the lead ion across the membrane.
Following binding, the transporter undergoes conformational changes that move the lead ion across the lipid bilayer. The structural basis for metal ion transport by DMT1 and NRAMP1 has been elucidated, showing how the protein alternates between outward-facing and inward-facing states to translocate the metal ion. Similar mechanisms have been described for SLC30A10-mediated manganese transport, where the transporter cycles through distinct conformations to move the metal ion across the membrane. Ferroportin also uses a conformational cycle for iron export, and its structural basis of ion transport and inhibition has been characterized. These studies provide a general framework for understanding how lead ions might be translocated by related transporters.
Release of lead ions into the cytoplasm or target compartment
In simple terms: The transporter then releases the lead ion inside the cell or into a specific compartment.
Once the lead ion has been translocated across the membrane, it is released into the cytoplasm or into a target organelle. The release step is driven by changes in the binding affinity of the transporter, which is coupled to the conformational cycle. For transporters such as DMT1, release into the cytoplasm allows the metal ion to participate in cellular processes or to be sequestered by metal-binding proteins. In the case of SLC30A10, release may occur into the cytoplasm or into vesicles, depending on the cellular context. The fate of the transported lead ion depends on the cell type and the presence of downstream metal-handling systems.
Regulation and coupling to other ion gradients
In simple terms: The transport process is controlled and often coupled to other ions.
Lead ion transport is not an isolated event; it is regulated and often coupled to other ion gradients. For example, DMT1-mediated transport is coupled to proton gradients, and the structural studies of SLC11 proteins have revealed the coupling mechanism. SLC30A10-mediated manganese transport is also regulated, and its molecular mechanisms have been characterized. Ferroportin-mediated iron export is inhibited by hepcidin, demonstrating that metal transport can be regulated by external signals. These regulatory mechanisms are likely to influence lead ion transport as well, although direct evidence for lead-specific regulation remains limited.
Integration with cellular metal homeostasis and detoxification
In simple terms: Once inside, lead can interfere with normal metal balance and detoxification.
After entering the cell, lead ions can interfere with the homeostasis of essential metals such as iron, manganese, and zinc. Zinc transporters play essential roles in myeloid cell function and host defense, and disruption of zinc homeostasis can impair immune responses. Similarly, ion transport and epithelial barrier dysfunction are observed in experimental models of ulcerative colitis, indicating that altered ion transport can contribute to disease. In cystic fibrosis, mutations in the CFTR ion channel lead to misfunction and guide therapy, illustrating how ion transport defects can be targeted. These examples highlight the importance of integrating lead ion transport into the broader context of cellular metal homeostasis and detoxification.
Key Genes Involved in GO:0015692 lead ion transport
The following genes and proteins have been implicated in metal ion transport and provide a framework for studying lead ion transport.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC11A2 (DMT1) | Divalent metal transporter 1; transports Fe2+, Mn2+, and other divalent metals | Structural basis for metal ion transport; potential lead transporter |
| SLC11A1 (NRAMP1) | Natural resistance-associated macrophage protein 1; metal ion transport in macrophages | Structural studies of SLC11 proteins inform lead transport mechanisms |
| SLC30A10 | Manganese transporter; mediates manganese efflux | Molecular mechanisms of metal transport; model for toxic metal handling |
| SLC40A1 (ferroportin) | Iron exporter; regulated by hepcidin | Structural basis of ion transport and inhibition; informs transport modulation |
| CFTR | Chloride and bicarbonate ion channel | Ion transport defects in cystic fibrosis; mutations guide therapy |
| SLC30A family (ZnT) | Zinc transporters | Essential for myeloid cell function and host defense |
| SLC39A family (ZIP) | Zinc importers | Zinc homeostasis and immune function |
| ATP7A/ATP7B | Copper-transporting ATPases | Metal transport and homeostasis; related to lead transport pathways |
| SLC6A19 | Neutral amino acid transporter | Ion transport in epithelial cells; related to barrier function |
| SLC26A3 | Chloride/bicarbonate exchanger | Ion transport in intestinal epithelium; linked to ulcerative colitis models |
| SLC9A3 (NHE3) | Sodium/hydrogen exchanger | Ion transport and epithelial barrier function |
| SLC12A2 (NKCC1) | Sodium-potassium-chloride cotransporter | Ion transport in epithelial cells |
| SLC4A1 (AE1) | Anion exchanger | Ion transport in red blood cells and kidney |
| SLC26A4 (pendrin) | Anion exchanger | Ion transport in inner ear and kidney |
| SLC7A11 | Cystine/glutamate antiporter | Redox and metal homeostasis; related to transport processes |
| SLC3A2 | Heavy subunit of amino acid transporters | Ion transport and cellular metabolism |
| SLC25A family | Mitochondrial carriers | Metal ion transport across mitochondrial membranes |
| MT1A/MT2A | Metallothioneins | Metal binding and detoxification; downstream of lead transport |
How Is lead ion transport Regulated?
Lead ion transport is regulated at multiple levels, although direct evidence for lead-specific regulation is limited. The activity of metal transporters such as DMT1 is coupled to proton gradients and can be modulated by cellular pH and metal availability. SLC30A10-mediated manganese transport is regulated by its own expression and localization, and mutations in SLC30A10 cause manganese-related disease. Ferroportin is regulated by the hormone hepcidin, which binds to ferroportin and induces its degradation, thereby controlling iron export. In epithelial tissues, ion transport is regulated by signaling pathways that control barrier function, and dysfunction of these pathways is observed in ulcerative colitis models. In cystic fibrosis, mutations in CFTR lead to misfunction of ion transport, and therapeutic strategies aim to correct the underlying defect. These examples illustrate that metal and ion transport processes are subject to complex regulation, which may also apply to lead ion transport.
lead ion transport and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC11A2 (DMT1) | Lead toxicity, iron homeostasis disorders | CRISPR knockout in cell lines; transport assays |
| SLC30A10 | Manganese transport disease, metal homeostasis | Knockout and point-mutation models; manganese transport assays |
| SLC40A1 (ferroportin) | Iron overload, hemochromatosis | Knock-in of disease mutations; iron export assays |
| CFTR | Cystic fibrosis | Point-mutation knock-in; ion transport assays |
| SLC30A/ZnT family | Immune dysfunction, infection susceptibility | Knockout in myeloid cells; infection models |
Lead toxicity and metal homeostasis disorders
Lead ion transport is directly relevant to lead toxicity, as the entry of lead into cells is required for its toxic effects. Divalent metal transporters such as DMT1 can mistransport lead, linking lead exposure to disruptions in iron and manganese homeostasis. SLC30A10 mutations cause manganese transport defects, demonstrating that impaired metal transport can lead to disease. Ferroportin mutations or dysregulation cause iron overload disorders, further highlighting the clinical importance of metal transport. Understanding lead ion transport may therefore inform strategies to reduce lead accumulation and its health consequences.
Cystic fibrosis and ion transport defects
Cystic fibrosis is caused by mutations in the CFTR ion channel, which lead to defective chloride and bicarbonate transport and subsequent organ damage. Although CFTR is not a lead transporter, the disease illustrates how ion transport defects can cause severe pathology and how mutations guide therapy. Studying lead ion transport in the context of epithelial ion transport may provide insights into how toxic metals exacerbate or mimic ion transport disorders.
Inflammatory and epithelial barrier diseases
Ion transport and epithelial barrier dysfunction are observed in experimental models of ulcerative colitis, where altered ion transport contributes to disease pathology. Zinc transporters are essential for myeloid cell function and host defense against infection, and disruption of zinc homeostasis can impair immune responses. These findings suggest that lead ion transport, by interfering with essential metal transport, could contribute to inflammatory and immune-related diseases.
From lead ion transport-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does SLC11A2 (DMT1) mediate lead ion transport? | CRISPR knockout of SLC11A2 in HEK293 or HeLa cells followed by lead uptake assays |
| What is the structural basis of lead recognition by SLC11 proteins? | Point mutations in the metal-binding site of SLC11A2; structural studies |
| Can SLC30A10 mutations alter metal transport specificity? | Knock-in of disease-associated SLC30A10 mutations; manganese and lead transport assays |
| How does ferroportin inhibition affect metal export? | Tagged knock-in of SLC40A1; live-cell imaging and transport assays |
| Does CFTR dysfunction affect lead sensitivity? | CFTR point-mutation knock-in models; ion transport and lead toxicity assays |
| Which transporters are required for lead uptake in epithelial cells? | CRISPR library screening in epithelial cell lines; lead uptake readout |
How to Study the lead ion transport Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioactive lead uptake assay | Rate and extent of lead ion transport | Quantifying transport activity of candidate transporters |
| Fluorescent lead probes | Intracellular lead levels and distribution | Live-cell imaging of lead transport |
| CRISPR knockout screen | Genes required for lead transport | Identifying novel transporters |
| Structural biology (cryo-EM/X-ray) | Three-dimensional structure of transporters | Mechanistic understanding of metal transport |
| Site-directed mutagenesis | Role of specific residues in transport | Testing metal-binding site function |
| Tagged knock-in imaging | Subcellular localization and trafficking | Visualizing transporter dynamics |
| RNA-seq | Transcriptional response to lead exposure | Identifying pathways affected by lead |
| Proteomics | Protein expression and interactions | Discovering lead-responsive proteins |
Transport assays using radioactive or fluorescent lead tracers
Direct measurement of lead ion transport can be performed using radioactive lead isotopes or fluorescent lead-sensitive probes. These assays allow researchers to quantify lead uptake or efflux in cells expressing candidate transporters. By comparing wild-type and CRISPR knockout cells, the contribution of specific transporters to lead ion transport can be determined. Similar approaches have been used to study manganese transport by SLC30A10 and iron transport by ferroportin.
Structural biology and mutagenesis
Structural studies of metal transporters such as DMT1, NRAMP1, SLC30A10, and ferroportin have revealed the molecular basis of ion recognition and translocation. Site-directed mutagenesis of metal-binding residues, combined with transport assays, can test whether specific residues are required for lead ion transport. These approaches provide mechanistic insights that can guide the design of inhibitors or modulators of lead transport.
CRISPR-based genetic screens
CRISPR knockout libraries can be used to systematically identify genes required for lead ion transport. Cells are infected with a pooled library, selected with lead exposure, and sgRNA abundance is analyzed by next-generation sequencing to identify enriched or depleted genes. This approach has been used to study metal transport and can be adapted to lead-specific screens. Bioinformatics analysis of screen data helps prioritize candidate transporters for validation.
Imaging and subcellular localization
Fluorescence microscopy and live-cell imaging can visualize the subcellular localization of metal transporters and the distribution of lead ions using lead-sensitive fluorescent probes. Tagged knock-in of transporters with fluorescent proteins allows real-time tracking of transporter trafficking and function. These methods complement biochemical transport assays and provide spatial information about lead ion transport.
How CRISPR Can Be Used to Study GO:0015692 lead ion transport
Knockout
CRISPR knockout of candidate transporters such as SLC11A2 (DMT1) or SLC30A10 can test whether they are required for lead ion transport. Knockout cell lines are generated by introducing frameshift mutations, and lead uptake is compared to wild-type cells. This approach provides causal evidence for the involvement of specific genes in lead transport.
Point Mutation
Point mutations in metal-binding residues of transporters can be introduced using CRISPR base editing or homology-directed repair. These models allow researchers to test the contribution of specific amino acids to lead ion recognition and translocation. For example, mutations in the metal-binding site of DMT1 can alter its ability to transport lead.
Knock-in
Knock-in of disease-associated mutations, such as those in SLC30A10 or CFTR, can model human disorders and assess their impact on lead ion transport. Tagged knock-in of transporters with fluorescent or affinity tags enables visualization and purification of the transporter for biochemical studies.
Overexpression
Overexpression of candidate transporters in cell lines can enhance lead ion transport and facilitate biochemical characterization. For example, overexpression of SLC11A2 or SLC30A10 can increase lead uptake, allowing detailed kinetic analysis. Overexpression models are also useful for testing inhibitors of lead transport.
How EDITGENE Supports lead ion transport Research
Researchers studying lead ion transport-related genes often need to determine whether a candidate gene is causally involved in lead uptake, efflux, or toxicity. EDITGENE provides a comprehensive suite of CRISPR-based services to generate knockout, point-mutation, knock-in, and overexpression cell models, as well as CRISPR library screening and bioinformatics support, enabling rigorous functional studies of lead ion transport.
Contact EDITGENE today to design your custom CRISPR model for lead ion transport research.
Frequently Asked Questions About lead ion transport
What is GO:0015692 lead ion transport?
GO:0015692 is a Gene Ontology biological process term defined as the directed movement of lead (Pb) ions into, out of, or within a cell, or between cells, by means of some agent such as a transporter or pore.
What genes are involved in lead ion transport?
Genes encoding divalent metal transporters such as SLC11A2 (DMT1), SLC11A1 (NRAMP1), SLC30A10, and SLC40A1 (ferroportin) are implicated in metal ion transport and provide a framework for lead ion transport studies.
How is lead ion transport studied?
Lead ion transport is studied using radioactive or fluorescent lead tracers, CRISPR knockout screens, structural biology, and imaging of tagged transporters.
Why is lead ion transport important for human health?
Lead is a toxic metal, and its transport into cells is required for its adverse effects; understanding transport mechanisms may inform strategies to reduce lead toxicity.
Which transporters can mistransport lead?
Divalent metal transporters such as DMT1 (SLC11A2) can mistransport lead because they recognize multiple divalent metals.
What diseases are linked to metal ion transport defects?
Diseases include cystic fibrosis (CFTR mutations), manganese transport disorders (SLC30A10), iron overload (ferroportin), and inflammatory conditions with epithelial barrier dysfunction.
Can CRISPR be used to study lead ion transport?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in lead ion transport.
What is the role of SLC30A10 in metal transport?
SLC30A10 mediates manganese transport, and its molecular mechanisms have been characterized, providing a model for toxic metal transport.
How does ferroportin relate to lead ion transport?
Ferroportin is an iron exporter whose structural basis of ion transport and inhibition has been elucidated, offering insights into metal transport mechanisms that may overlap with lead.
What experimental models are available for lead ion transport research?
Models include CRISPR knockout cell lines, point-mutation knock-ins, tagged knock-ins, overexpression lines, and genome-wide CRISPR screens.
Conclusion
GO:0015692 (lead ion transport) is a critical biological process that describes the movement of toxic lead ions across cellular membranes. Although no dedicated lead transporter has been identified, structural and mechanistic studies of divalent metal transporters such as DMT1, NRAMP1, SLC30A10, and ferroportin provide a strong foundation for understanding how lead may be transported. The clinical relevance of metal transport is underscored by diseases such as cystic fibrosis, manganese transport disorders, and iron overload. CRISPR-based models and advanced screening methods are essential tools for identifying and validating the genes involved in lead ion transport. EDITGENE offers comprehensive services to support these studies and accelerate discoveries in metal transport biology.
References
- 2. Farinha CM et al.. 2022. Molecular mechanisms of cystic fibrosis - how mutations lead to misfunction and guide therapy.. Biosci Rep 42(7) PMID: 35707985
- 4. Liziczai M et al.. 2025. Structural basis for metal ion transport by the human SLC11 proteins DMT1 and NRAMP1.. Nat Commun 16(1):761 PMID: 39824808
- 5. Shen X et al.. 2025. Molecular mechanisms of SLC30A10-mediated manganese transport.. Nat Commun 16(1):8581 PMID: 41022720
- 6. Sandle GI et al.. 2025. Ion transport and epithelial barrier dysfunction in experimental models of ulcerative colitis.. Am J Physiol Gastrointest Liver Physiol 328(6):G811-G830 PMID: 40184259
- 7. Sapkota M et al.. 2018. Essential Role of Zinc and Zinc Transporters in Myeloid Cell Function and Host Defense against Infection.. J Immunol Res 2018:4315140 PMID: 30417019
- 8. Pan Y et al.. 2020. Structural basis of ion transport and inhibition in ferroportin.. Nat Commun 11(1):5686 PMID: 33173040
